Methotrexate manufacturers and suppliers

Methotrexate suppliers

Properties

Melting point:: 195°C

Boiling point:: 561.26°C (rough estimate)

alpha: +17～+24°(D/20℃)(c=1,Na2CO3 soln.)(calculated on the dehydrous basis)

Density: 1.4080 (rough estimate)

refractive index: 1.6910 (estimate)

Flash point:: 11℃

storage temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

solubility: H₂O: insoluble

form: powder

pka: pKa 3.04/4.99(H2O,t =25,I=0.0025) (Uncertain)

Water Solubility: Insoluble. <0.1 g/100 mL at 19 ºC

Sensitive: Light Sensitive & Hygroscopic

Merck: 14,5985

BRN: 70669

BCS Class: 3

Stability:: Stable, but light sensitive and hygroscopic. Incompatible with strong acids, strong oxidizing agents. Store at -15C or below.

InChIKey: FBOZXECLQNJBKD-ZDUSSCGKSA-N

Safety Information

Symbol(GHS): GHS06,GHS08

Signal word: Danger

Hazard statements: H301-H315-H319-H341-H360D

Precautionary statements: P201-P301+P310+P330-P302+P352-P305+P351+P338

Hazard Codes: T,F

Risk Statements: 61-25-36/38-46-39/23/24/25-23/24/25-11

Safety Statements: 53-26-36/37-45-36/37/39-36-16

RIDADR: UN 2811 6.1/PG 3

WGK Germany: 3

RTECS: MA1225000

F: 3-8-10

TSCA: Yes

HazardClass: 6.1(b)

PackingGroup: III

HS Code: 29335995

Toxicity: LD50 oral in rat: 135mg/kg

Use

The drug is available in 50-, 100-, 200-, and 1,000-mg vialsfor IV use. Methotrexate is used to treat several cancer typesincluding breast cancer, bladder cancer, colorectal cancer,and head and neck cancer. The mechanism of action ofmethotrexate involves inhibition of DHFR leading to a depletionof critical reduced folates. The reduced folates arenecessary for biosynthesis of several purines and pyrimidines.Resistance to methotrexate can occur because ofdecreased carrier-mediated transport of drug into cells orincreased expression of the target enzyme DHFR. Oralbioavailability varies with dose because of saturable uptakeprocesses, and high doses are required to reach therapeuticlevels in the CNS. The majority of drug dosage is excretedunchanged in the urine. The renal excretion of methotrexateis inhibited by several carboxylic acid drugs such as penicillins,probenecid, nonsteroidal anti-inflammatory agents,and aspirin. Methotrexate enhances 5-FU antitumor effectswhen given 24 hours prior to the fluoropyrimidine.Methotrexate toxicity includes myelosuppression, mucositis,nausea, vomiting, severe headaches, renal toxicity, acutecerebral dysfunction, skin rash, and hyperpigmentation.

You can find Methotrexate suppliers, manufacturers, and distributors from countries such as China, United States and the India here. Browse to the tetrahydrofuran product information displayed by the supplier, as well as the supplier's contact and capability information.